The Chordoma Foundation and some of its philanthropic partners announced that they will launch a competition offering $500,000 in prizes for the discovery of drugs targeting the protein TBXT, a ...
Cambridge, MA–based Mersana Therapeutics announced today that its B7-H4–targeted antibody–drug conjugate emilatug ledadotin (XMT-1660) elicited a complete response in 23% (six of 26) of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback